Pegaptanib
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 65 (11), 1571-1577
- https://doi.org/10.2165/00003495-200565110-00010
Abstract
▴ Pegaptanib, an aptamer, is an antagonist of vascular endothelial growth factor that has shown efficacy in the treatment of patients with exudative age-related macular degeneration (AMD). ▴ In two randomised, double-masked trials in patients with exudative AMD (n = 1208), the proportion of responders (those losing <15 letters of visual acuity) at 54 weeks was significantly higher in intravitreous pegaptanib 0.3mg recipients than in those receiving sham injections (70% vs 55%; p < 0.001). These trials were conducted concurrently and analysed as a single study; the treatments were given every 6 weeks for 48 weeks. The improvement in visual acuity with pegaptanib was maintained in a 1-year extension of these trials. ▴ Similar favourable results with pegaptanib 0.3mg were seen in terms of the secondary efficacy endpoints (e.g. proportion of patients experiencing severe loss of visual acuity or legal blindness in the study eye). These vision-improving effects of pegaptanib were associated with beneficial angiographic effects. ▴ Intravitreous pegaptanib 0.3–3mg was well tolerated with most ocular adverse events being mild-tomoderate and transient. Serious injection-related adverse events occurred in ≤1.3% of patients treated with pegaptanib. There were no systemic adverse events that could be definitely attributed to pegaptanib.Keywords
This publication has 16 references indexed in Scilit:
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004
- Prevalence of Age-Related Macular Degeneration in the United StatesAmerican Journal of Ophthalmology, 2004
- The Epidemiology of Age-Related Macular DegenerationInternational Ophthalmology Clinics, 2004
- Innovative Treatments for Exudative Age-Related Macular DegenerationInternational Ophthalmology Clinics, 2004
- Current and Future Treatment Options for Nonexudative and Exudative Age-Related Macular DegenerationDrugs & Aging, 2004
- Potential Public Health Impact of Age-Related Eye Disease Study ResultsAmerican Journal of Ophthalmology, 2003
- Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degenerationOphthalmology, 2003
- PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2002
- Overexpression of Vascular Endothelial Growth Factor (VEGF) in the Retinal Pigment Epithelium Leads to the Development of Choroidal NeovascularizationThe American Journal of Pathology, 2000
- Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitroIn Vitro Cellular & Developmental Biology – Animal, 1999